Douglas Lane & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$169M Sell
663,667
-9,036
-1% -$2.11M 2.29% 4
2026
Q1
$164M Sell
672,703
-7,524
-1% -$1.75M 2.37% 4
2025
Q4
$141M Buy
680,227
+12,854
+2% +$2.54M 1.93% 7
2025
Q3
$124M Buy
667,373
+34,948
+6% +$5.99M 1.72% 8
2025
Q2
$96.6M Buy
632,425
+14,750
+2% +$2.27M 1.4% 17
2025
Q1
$102M Buy
617,675
+18,289
+3% +$2.86M 1.51% 14
2024
Q4
$86.7M Buy
599,386
+6,526
+1% +$1.01M 1.22% 21
2024
Q3
$96.1M Buy
592,860
+15,508
+3% +$2.47M 1.32% 18
2024
Q2
$84.4M Buy
577,352
+32,098
+6% +$4.77M 1.2% 25
2024
Q1
$86.3M Buy
545,254
+24,686
+5% +$3.93M 1.22% 24
2023
Q4
$81.6M Buy
520,568
+40,363
+8% +$6.19M 1.26% 27
2023
Q3
$74.8M Buy
480,205
+33,412
+7% +$5.51M 1.26% 25
2023
Q2
$74M Buy
446,793
+34,122
+8% +$5.51M 1.19% 32
2023
Q1
$64M Buy
412,671
+16,174
+4% +$2.61M 1.06% 42
2022
Q4
$70M Buy
396,497
+36,277
+10% +$6.26M 1.17% 41
2022
Q3
$58.8M Buy
360,220
+3,369
+0.9% +$570K 1.09% 37
2022
Q2
$63.3M Buy
356,851
+7,638
+2% +$1.36M 1.08% 38
2022
Q1
$61.9M Buy
349,213
+37,212
+12% +$6.33M 0.87% 47
2021
Q4
$53.4M Buy
312,001
+48,438
+18% +$7.93M 0.71% 56
2021
Q3
$42.6M Buy
263,563
+23,548
+10% +$4.02M 0.61% 69
2021
Q2
$39.5M Buy
240,015
+21,764
+10% +$3.6M 0.55% 74
2021
Q1
$35.9M Buy
218,251
+23,243
+12% +$3.76M 0.56% 74
2020
Q4
$30.7M Buy
195,008
+39,822
+26% +$5.88M 0.51% 77
2020
Q3
$23.1M Buy
155,186
+7,966
+5% +$1.18M 0.46% 74
2020
Q2
$20.7M Buy
147,220
+22,898
+18% +$3.34M 0.44% 76
2020
Q1
$16.3M Buy
124,322
+58,700
+89% +$8.33M 0.43% 74
2019
Q4
$9.57M Buy
65,622
+1,117
+2% +$152K 0.18% 101
2019
Q3
$8.35M Buy
64,505
+407
+0.6% +$53.6K 0.17% 105
2019
Q2
$8.93M Sell
64,098
-1,581
-2% -$219K 0.17% 103
2019
Q1
$9.18M Buy
65,679
+405
+0.6% +$54.2K 0.19% 100
2018
Q4
$8.42M Sell
65,274
-2,921
-4% -$407K 0.2% 101
2018
Q3
$9.42M Sell
68,195
-558
-0.8% -$74.2K 0.19% 99
2018
Q2
$8.34M Sell
68,753
-1,853
-3% -$231K 0.18% 99
2018
Q1
$9.05M Sell
70,606
-2,709
-4% -$366K 0.2% 98
2017
Q4
$10.2M Sell
73,315
-7,315
-9% -$1.02M 0.22% 97
2017
Q3
$10.5M Buy
80,630
+1,858
+2% +$246K 0.24% 93
2017
Q2
$10.4M Sell
78,772
-3,192
-4% -$407K 0.25% 94
2017
Q1
$10.2M Buy
81,964
+3,680
+5% +$440K 0.25% 92
2016
Q4
$9.02M Sell
78,284
-1,514
-2% -$175K 0.23% 101
2016
Q3
$9.43M Sell
79,798
-4,327
-5% -$525K 0.25% 98
2016
Q2
$10.2M Sell
84,125
-1,545
-2% -$176K 0.29% 99
2016
Q1
$9.27M Buy
+85,670
New +$8.87M 0.25% 104

Other funds holding JNJ

Douglas Lane & Associates's JNJ Position: Q2 2026 in Review

Douglas Lane & Associates reduced its Johnson & Johnson (JNJ) stake by 1.3% in Q2 2026, selling an estimated $2.11M and leaving 663,667 shares worth $169M. The position accounts for 2.29% of the portfolio, ranked #4.

Douglas Lane & Associates first reported a position in JNJ in Q1 2016 and has held it in 42 quarters since. 4,655 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Douglas Lane & Associates held 663,667 shares of Johnson & Johnson worth $169M as of Q2 2026.
  • Douglas Lane & Associates sold 9,036 Johnson & Johnson shares in Q2 2026, an estimated $2.11M.
  • Johnson & Johnson made up 2.29% of Douglas Lane & Associates's portfolio in Q2 2026, its #4 holding.
  • Douglas Lane & Associates first reported a position in Johnson & Johnson in Q1 2016 and has held it in 42 quarters since.
  • 4,655 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.